UK drug legislation has had limited impact on the availability of novel psychoactive substances (NPS), with international regulations playing a far greater role in shaping the UK drug market. NPS are chemically engineered substances designed to mimic the effects of traditional controlled drugs such as opioids, stimulants, and cannabinoids. These compounds pose significant health risks […]